ALK and non-small cell lung carcinoma: In our investigation, circulating microRNAs from plasma samples of patients with ALK-positive NSCLC (n = 3), patients with ALK-negative NSCLC (n = 3), and healthy subjects (n = 3) were analyzed by microarray (Human miRNA Microarray, G4872A; Agilent Technologies, Santa Clara, CA, USA; Gene Expression Omnibus accession no. GSE94536) and real-time reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) technologies.